These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Jun 12, 2019
Publication demonstrates specific U2AF1 splicing factor mutations induce oncogenic IRAK4-L isoform and activate innate immune pathways in myeloid malignancies
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a publication titled "U2AF1 mutations...
-
May 14, 2019
-- Management to host conference call today at 4:30 p.m. EDT --
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter...
-
May 7, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first...
-
May 6, 2019
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached...
-
Apr 10, 2019
Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from...
